Bolt biotherapeutics presents updated preclinical data for bdc-4182 and key learnings from phase 1 dose-escalation trial of bdc-1001 at sitc 39th annual meeting

Bdc-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies bdc-4182 outperformed cytotoxic claudin 18.2 adcs in syngeneic model learnings from bdc-1001 data suggest boltbody™  isacs with enhanced immune activation could offer greater efficacy, warranting further testing redwood city, calif., nov. 07, 2024 (globe newswire) -- bolt biotherapeutics (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for bdc-4182, a next-generation boltbody™ isac clinical candidate targeting claudin 18.2, and provided key learnings from its phase 1 dose-escalation trial of bdc-1001 at the 39th annual meeting of the society for immunotherapy of cancer (sitc), being held in houston, texas from november 6-10, 2024.
BDC Ratings Summary
Quant
BDC Quant Ranking
Sector
Industry
Quant Rating
Quant Score